Eli Lilly and Company (NYSE:LLY) Shares Purchased by Mackenzie Financial Corp

Mackenzie Financial Corp boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 274,481 shares of the company's stock after purchasing an additional 5,577 shares during the period. Mackenzie Financial Corp's holdings in Eli Lilly and Company were worth $211,899,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Grassi Investment Management grew its stake in shares of Eli Lilly and Company by 0.3% in the fourth quarter. Grassi Investment Management now owns 79,512 shares of the company's stock worth $61,383,000 after acquiring an additional 225 shares in the last quarter. Elevate Capital Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth $262,000. Capital & Planning LLC lifted its position in shares of Eli Lilly and Company by 15.6% during the 4th quarter. Capital & Planning LLC now owns 481 shares of the company's stock worth $371,000 after purchasing an additional 65 shares during the last quarter. Garner Asset Management Corp lifted its position in shares of Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after purchasing an additional 12 shares during the last quarter. Finally, Enclave Advisors LLC lifted its position in shares of Eli Lilly and Company by 7.9% during the 4th quarter. Enclave Advisors LLC now owns 410 shares of the company's stock worth $317,000 after purchasing an additional 30 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

LLY has been the subject of several recent analyst reports. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Trading Down 0.2%

Shares of Eli Lilly and Company stock opened at $713.99 on Friday. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company's 50-day simple moving average is $789.29 and its 200-day simple moving average is $803.00. The firm has a market cap of $676.67 billion, a price-to-earnings ratio of 60.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the firm earned $2.58 earnings per share. The company's revenue was up 45.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.84%. Eli Lilly and Company's payout ratio is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.